1 Syncope and Related Injuries after Vaccination Wan-Ting Huang, MD Immunization Safety Office Office of the Chief Science Officer The 42 nd National Immunization.

Slides:



Advertisements
Similar presentations
1 Cover page Let’s Review Changes in CDC Recommendations in 2011 Carolee’s Corner January 2012 MPCA
Advertisements

Vaccine Update and Refresher for Immunizations: 2012 Krista D. Capehart, PharmD, MSPharm, AE-C David G. Bowyer, R. Ph. Assistant Professors of Pharmacy.
Julianne Gee, MPH Immunization Safety Office
IMMUNIZATION Immunization??? Reduce mortality and morbidity of mathernal and baby.
Improving The Clinical Care of Children and Adolescents With Mild Traumatic Brain Injury Madeline Joseph, MD, FACEP, FAAP Professor of Emergency Medicine.
Hepatitis A and Hepatitis A Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.
ACIP Meeting Update November 4 th
Pertussis Kate Goheen March 25, 2009 Weill Cornell Medical College Class of 2010.
Adolescent Vaccines What every parent needs to know!
Tom Shimabukuro, MD, MPH, MBA Immunization Safety Office Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious.
Hepatitis web study H EPATITIS W EB S TUDY Hepatitis A: Epidemiology Presentation Prepared by: David Spach, MD and Nina Kim, MD Last Updated: May 31, 2011.
CDC Influenza Vaccine Safety Monitoring Immunization Safety Office (ISO) Penina Haber John Iskander Authors have no financial and other conflict of interest.
Tom Shimabukuro, MD, MPH, MBA Immunization Safety Office Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious.
Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.
HPV Vaccine.
Preventive Care and Sexual Health Information for Tweens and Teens
Adult Immunization 2010 Influenza Segment This material is in the public domain This information is valid as of May 25, 2010.
Adult Vaccination Update Walter W. Williams, M.D., M.P.H. Medical Epidemiologist, NCIRD National Adult and Influenza Immunization Summit Provider Work.
Case Study: Jennifer and James Amy B. Middleman, MD, MSEd, MPH Assistant Professor, Department of Pediatrics, Adolescent Medicine Section, Baylor College.
Vaccine Safety Concerns  Past of vaccines  Now most parents have never seen a case of diphtheria, measles, or other once- common diseases.  They therefore.
Varicella Zoster Virus Herpesvirus (DNA) Primary infection results in varicella (chickenpox) Recurrent infection results in herpes zoster (shingles) Short.
What's New on the Child and Adolescent Immunization Schedules William L. Atkinson, MD, MPH National Center for Immunization and Respiratory Diseases William.
Childhood Immunization Update for WIC and Clerical Personnel Presented by: Date:
MEASLES VACCINATION 2015 Update Susan Reeser RN, BSN (406)
1 1 Immunization Update 2011 Connecticut Immunization Teleconference April 19, 2011 William Atkinson, MD, MPH National Center for Immunization and Respiratory.
Adult Immunization 2010 Tetanus, Diphtheria and Pertussis Segment This material is in the public domain This information is valid as of May 25, 2010.
TM 2011 Immunization Recommendations H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Boston Floating Hospital for Children.
VAERS Analysis SaneVax Inc. ©2012. Total Adverse Events Gardasil (HPV4)was approved for use in June This chart represents the vaccines most frequently.
ADOLESCENT IMMUNIZATIONS
The potential impact of adherence to a guideline on the utilization of head CT scans in traumatic head injury patients. Frederick K. Korley M.D.
Background CDC licensed VZV vaccine in 1995 The virus is known to enter through the respiratory tract and conjunctiva, where it then enters the bloodstream.
1 LYMErix® Safety Data Reported to the Vaccine Adverse Event Reporting System (VAERS) Robert Ball, M.D., M.P.H., Sc.M. Division of Epidemiology Office.
5th Annual Advocacy Project: ImmuneWise Section on Medical Students, Residents, and Fellowship Trainees
June 2010 California Pertussis Update. Pertussis Background Pertussis is the most poorly controlled vaccine- preventable disease  Incidence increasing.
SMFM Clinical Practice Guidelines Tdap Vaccination in pregnancy Society of Maternal Fetal Medicine with the assistance of Neil Silverman, MD Published.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
Presentation Outline Introduction Reasons to Immunize Adults: Make the Case Myths vs. Facts Barriers to Adult Immunization The Ask Adult Immunization Resources.
Update on the febrile seizure signal after influenza vaccine David Martin, MD, MPH Pharmacovigilance Branch Division of Epidemiology Office of.
Treat with confidence. Trusted answers from the American Academy of Pediatrics. The 2015 Childhood Immunization Schedule H. Cody Meissner, MD, FAAP Floating.
Pertussis and Pertussis Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Progress in adolescent vaccination coverage levels in the United States National Immunization Conference Washington, DC March 31, 2011 Shannon Stokley,
Vaccination Administration Errors Reported to the Vaccine Adverse Event Reporting System (VAERS) Elaine R. Miller, RN, MPH Beth Hibbs, RN, MPH Barbara.
National Immunization Conference March 30, 2011 Elaine R. Miller, RN, MPH Beth Hibbs, RN, MPH What Healthcare Providers Need to Know about the Vaccine.
Diabetes and Obesity Journal Club Carina Signori Endocrinology Fellow
Meningococcal Disease and Meningococcal Conjugate Vaccine National Immunization Conference March 7, 2007.
1 Review of the Vaccine Adverse Event Reporting System (VAERS) Beth Hibbs RN, MPH; Elaine Miller RN, MPH Immunization Safety Office (ISO) Division of Healthcare.
Beth Hibbs, RN, MPH Immunization Safety Office - Division Of Healthcare Quality Promotion, Centers for Disease Control and Prevention Vaccination Errors.
Job Corps Webinar: Immunizations John Kulig MD MPH Lead Medical Specialist September 29 & 30, 2010.
Post-vaccination Syncope: Follow-up Survey of Reports to Vaccine Adverse Event Reporting System (VAERS) 44 th National Immunization Conference
Date of download: 6/21/2016 From: Recommended Adult Immunization Schedule: United States, October 2007–September 2008(1) Ann Intern Med. 2007;147(10):
1 Review of the Evidence: Risk for Wheezing after Live, Attenuated Influenza Vaccine (LAIV: FluMist ® ) in Children Aged 2–4 Years Karen R. Broder, MD.
ADULT IMMUNIZATION An Unexploited Opportunity for Prevention William Schaffner, MD Professor of Preventive Medicine Department of Health Policy Professor.
1 Diphtheria Toxoid-containing Vaccines: Safety Evidence for ACIP* Recommendations on Intervals and Administration Sequence Karen R. Broder, MD, FAAP Lieutenant.
Jennifer Rittenhouse Cope, MD EIS Officer North Dakota Department of Health Factors Associated with Tdap and Meningococcal Vaccination Coverage Among Middle.
TM Immunization Adults Inactivated Influenza Vaccine Vaccine Adverse Event Reporting System (VAERS) – 14 Years Experience Penina Haber 39 th National Immunization.
TM Influenza Vaccine Safety in Children: Data from VAERS John Iskander MD MPH Gina Mootrey DO MPH Penina Haber MPH Roseanne English-Bullard BS.
Review of VAERS reports involving seizures following 7-valent pneumococcal conjugate vaccine (PCV7) Scott Campbell, RN, MSPH* John Iskander, MD, MPH* Robert.
ACIP Feb , 2007 Guillain-Barré Syndrome (GBS) Among Recipients of Meningococcal Conjugate Vaccine (MCV4,Menactra®) Update Oct Jan Robert.
The effect of patient education on tetanus, diphtheria, and pertussis (Tdap) immunization rates in post-partum women.
Traumatic Brain Injury (TBI) in the Primary Care Setting
Robert Ball, M.D., M.P.H., Sc.M. Division of Epidemiology
Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events
What’s New in Adult Immunization
Number of catch-up doses needed (n = 200) at admission and at 1-month follow-up by vaccine type among 95 children found to be underimmunized per ACIP guidelines.
Pediatric Inactivated Influenza Vaccine Safety VAERS Reports for Trivalent Inactivated Influenza Vaccine (TIV) in Infants/Toddlers Ann McMahon, MD, MS.
Physician Adoption of Adolescent Tdap Recommendations
Trudy V. Murphy, MD March 8, 2006 National Immunization Program
Adolescent and Adult ACIP Update
Karen A. Cullen, Diana L. Bartlett, C. Robinette Curtis
Immunization Safety Office (ISO) National Immunization Program (NIP)
Presentation transcript:

1 Syncope and Related Injuries after Vaccination Wan-Ting Huang, MD Immunization Safety Office Office of the Chief Science Officer The 42 nd National Immunization Conference Atlanta, GA March 17, 2008

2 Vasovagal Syncope Transient loss of consciousness as a consequence of decreased brain perfusion Bradycardia, vasodilatation or hypotension resulting from abnormal sympathetic reflex Elicited by a variety of stimuli in settings of fear or emotional distress Occurs after medical procedures, including vaccinations

3 General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) * “… vaccine providers should strongly consider observing patients for 15 minutes after they are vaccinated. If syncope develops, patients should be observed until symptoms resolve.” * MMWR 2006; 55 (No. RR-15)

4 Learning Objectives Describe trends in syncope events reported to Vaccine Adverse Event Reporting System (VAERS) Identify potential risk factors for postvaccination syncope Understand recommended strategies to prevent postvaccination syncope and related injury

5 Vaccine Adverse Event Reporting System (VAERS) National passive surveillance system Jointly operated by CDC and FDA since November 1990 Covering all U.S. licensed vaccines Receives >20,000 reports per year Subject to well-described limitations including underreporting and reporting bias

6 Published VAERS Data on Syncope Serious injuries with at least one fatality have occurred * 89% occurred within 15 minutes † ; 24% with convulsive movements mimicking seizures VAERS data, 1990 – 2004 ¶ (n=3,168) 35% were among persons aged 10–18 years 14% resulted in hospitalization for injury or medical evaluation * Woo EJ et al. Arch Pediatr Adolesc Med 2005; † Braun MM et al. Arch Pediatr Adolesc Med 1997; ¶ MMWR 2006; 55 (No. RR-15)

7 Methods Population: VAERS reports received Jan 1, 2005–Jul 31, 2007 Case definition: MedDRA ® coding terms * — “syncope” or “syncope, vasovagal” Case-patients aged ≥5 years Syncope onset <1 calendar day after vaccination Available records reviewed for selected reports * Medical Dictionary for Regulatory Activities (MedDRA ® )

8 Adverse Events * Reported to VAERS, January 1, 2002–July 31, 2007 Year2002– –2007 n=23,934n=25,861 Adverse eventsn(%)n Syncope203(1)463(2) Serious † syncope 20(10) ¶ 33(7) ¶ * Case-patients aged ≥ 5 years † Defined by FDA as resulting in death, life-threatening illness, hospitalization, prolong hospitalization or disability; according to information provided by the reporter of the adverse event ¶ Proportion of serious reports among all syncope reports

9 MCV4 † February 10, 2005 ¶ Tdap † June 29, 2005 ¶ HPV † June 29, 2006 ¶ *Case-patients aged ≥5 years † MCV4: meningococcal conjugate vaccine; Tdap: tetanus toxoid, reduced diphtheria toxoid and acellular pertusis vaccine; HPV: quadrivalent human papillomavirus vaccine ¶ Date of ACIP Vaccines For Children (VFC) Program vote 2005

10 *Age or sex unknown (n=5) are not included 229 (49%) 49 (24%)

11 Vaccines Associated with Adverse Events in VAERS, January 1, 2005–July 31, 2007 SyncopeAll adverse events n(%)n HPV229(19)1,184(100) MCV490(13)697(100) Tdap64(8)816(100) HPV, MCV4, and/or Tdap291(12)2,355(100) Other vaccine(s)172(<1)23,506(100) Total463(2)25,861(100) *Categories of types of vaccines were not mutually exclusive

12 Number of Vaccines * Administered and Syncope, January 1, 2005–July 31, 2007 Number of vaccines * SyncopeAll adverse events given concurrentlyn(%)n 1182(11)1,655(100) ≥2≥2109(16)700(100) 266(15)441(100) 330(17)181(100) ≥4≥413(17)78(100) Total291(12)2,355(100) *Including vaccine types of HPV, MCV4, and/or Tdap

13 Syncope Associated with Injuries in VAERS Reports, January 1, 2005–July 31, 2007 (n=41 * ) Adolescent (11–18 years), n=31 Females, n=22 (71%) Males, n=9 (29%) Syncope onset after vaccination: 20 (49%) within 5 minutes 33 (80%) within 15 minutes Serious † cases, n=10 (24%) * Excludes cases with unknown onset intervals (n=14) † Defined as adverse events provided by the reporter which result in death, life- threatening illness, hospitalization, prolong hospitalization or disability

14 Complications in Syncope-related Injuries, January 1, 2005–July 31, 2007 (n=41*) * Excluded cases with unknown onset intervals (n=14) † Each injury may result in multiple complications Categoryn(%) † Facial lacerations717 Concussions37 Skull fractures37 Intracranial hemorrhage25 Tooth injury25 Facial palsy12 Car accidents12 Falls without complication2561

15 Example of Injury Related to Postvaccination Syncope An adolescent girl aged 13 years fainted within 10 minutes of receiving HPV and MCV4. She fell backward, hit her head on the carpeted floor of the clinic and was admitted to the pediatric intensive care unit because of skull fractures and subarachnoid hemorrhage. She had recovered completely within 6 months after the injury.

16 Example of Injury Prevented from Postvaccination Syncope An adolescent girl aged 16 years felt dizzy and was observed to have pallor within 5 minutes of receiving HPV. While being taken back to the examination room, she fainted but the clinic physician prevented her from falling. She was observed for 30 minutes in the clinic and completely recovered.

17 Limitations Cannot calculate syncope incidence rate based on VAERS data Underreporting of adverse events Lack of age or sex specific vaccine doses administered VAERS MedDRA ® coding terms may not reflect diagnosis accurately Cannot determine if syncope related to vaccine, targeted groups or both

18 Conclusions Since 2005, an increase in the number of VAERS syncope reports among: Females aged 11–18 years Nonserious reports Reports associated with vaccines recommended for adolescents Syncope-related injury can be serious but may be preventable by following the waiting period recommendations

19 Areas for Research Address age or sex specific incidence of postvaccination syncope Evaluate adherence and barriers to waiting period Evaluate efficacy of waiting period and other measures to prevent secondary injury Provide interventions for use by clinicians to predict or prevent syncope after vaccination

20 Recommendations and Guidance Advisory Committee on Immunization Practices, 2006 * “vaccine providers should strongly consider observing patients for 15 minutes after they are vaccinated.” American Academy of Pediatrics, 2006 † “personnel should be aware of presyncopal manifestations and take appropriate measures to prevent injuries;” “having vaccine recipients sit or lie down for 15 minutes after immunization could avert many syncope episodes and secondary injuries.” * MMWR 2006; 55 (No. RR-15); † American Academy of Pediatrics Red Book: Report of the Committee on Infectious Diseases, 27 th ed.

21 Acknowledgements CDC Karen Broder Julianne Gee John Iskander Andrew Kroger Laura Leidel Lauri Markowitz Elaine R. Miller FDA Robert Ball M. Miles Braun Hector Izurietta Andrea Sutherland * Emily J. Woo * Johns Hopkins University, MD

22 Additional Slides

23 *Case-patients aged ≥5 years † HPV: quadrivalent human papillomavirus vaccine

24 *Case-patients aged ≥5 years † MCV4: meningococcal conjugate vaccine

25 Vaccines Associated with Adverse Events in VAERS, January 1, 2002–December 31, 2004 SyncopeAll adverse events n(%)n HBV † 76(6)1,300(100) TIV † 47(2)2,425(100) Td † 40(5)886(100) Other vaccine(s)58(<1)19,572(100) Total203(1)23,934(100) *Categories of types of vaccines were not mutually exclusive † TIV: trivalent inactivated influenza virus vaccine; HBV: recombinant hepatitis B vaccine; Td: tetanus and diphtheria toxoid adsorbed for adult use

26 Vaccines Associated with Syncope Reports in VAERS, January 1, 2005–July 31, 2007 One vaccine given n=302 Multiple vaccines given concurrently n=161 n(%)n HPV156(52)63(39) * MCV415(5)75(47) * Tdap11(4)53(33) * HPV, MCV4 and/or Tdap182(60)109(68) Other vaccine(s)120(40)52(32) * Not mutually exclusive categories

27 Injection-site Adverse Events *, Days 1–5 After Any Vaccination with HPV HPVAluminum- containing placebo Saline placebo (n=5,088)(n=3,470)(n=320) (%) Pain Mild/Moderate Severe Swelling Erythema * Female participants aged 9 – 23 years in the detailed safety data † Source: MMWR; 2007; No. 56(RR-2)